- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07587047
Adia Med of Winter Park LLC Lower Back Pain Research Study
16 juni 2026 uppdaterad av: Adia Med of Winter Park LLC
A Randomized, Placebo-Controlled, Single-Blind, Crossover Study to Evaluate the Safety and Preliminary Efficacy of a Single Intravenous AdiaVita (Umbilical Cord Blood - Stem Cells and Exosomes) Infusion in Adults With Chronic Mechanical Lower Back Pain
The goal of this clinical study is to evaluate the safety and preliminary efficacy of an investigational umbilical cord blood-derived stem cell and exosome infusion in adults with chronic lower back pain associated with degenerative spine disease.
The primary questions this study aims to answer are whether the investigational infusion is safe and well tolerated and whether treatment may reduce pain and improve physical function and quality of life.
Researchers will compare the investigational infusion to a placebo (saline solution) to evaluate potential treatment effects in participants with chronic mechanical lower back pain.
Participants will receive either the investigational infusion or placebo intravenously during a study visit, complete pain, disability, and quality-of-life assessments, undergo magnetic resonance imaging (MRI) and laboratory testing, and attend follow-up evaluations over a 6-month period.
Participants initially assigned to placebo may later receive the investigational treatment during an open-label crossover phase of the study.
Studieöversikt
Status
Rekrytering
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The study evaluates the safety and preliminary efficacy of a single intravenous infusion of an investigational umbilical cord blood-derived stem cell and exosome product in adults with chronic mechanical lower back pain.
It is designed as a randomized, placebo-controlled, single-blind crossover clinical trial involving approximately 100 participants between 18 and 85 years old.
The research primarily aims to characterize short-term safety while also exploring potential improvements in pain, disability, quality of life, MRI findings, and inflammatory biomarkers.
Participants must have chronic low back pain lasting at least three months and MRI-confirmed degenerative spinal pathology such as disc disease, disc bulges, or facet joint osteoarthritis.
The study excludes pregnant individuals, prisoners, people with active infections or malignancies, and those who recently underwent lumbar surgery or spinal injections.
Participants are recruited through clinic databases, physician referrals, advertisements, and outreach to people previously interested in regenerative therapies.
Researchers emphasize that the intervention is investigational, not FDA approved for lower back pain, and not guaranteed to provide improvement.
Participants are randomized to receive either the investigational infusion or placebo saline administered intravenously over approximately five minutes with at least one hour of monitoring afterward.
Those initially assigned to placebo may later receive the investigational product during an open-label crossover at three months.
Outcome measures include Visual Analog Scale pain scores, Oswestry Disability Index assessments, SF-36 quality-of-life surveys, MRI reviews, and inflammatory biomarker testing.
Study visits occur during screening, baseline, and follow-up evaluations at months 1, 3, and 6. Potential risks include infusion reactions, allergic responses, infection, thrombotic complications, and unknown long-term biologic effects.
The protocol includes safety safeguards such as pre-infusion screening, emergency response equipment, structured adverse-event monitoring, and oversight by an independent Data Safety Monitoring Board.
Researchers state that direct benefits are uncertain, although some participants may experience reduced pain or improved function and quality of life.
Participants are required to pay a $5,000 study fee plus possible MRI costs, and the protocol acknowledges that this may bias enrollment toward individuals with higher socioeconomic status.
The study is exploratory in nature and intended to generate feasibility, safety, and effect-size data to guide future larger clinical trials rather than establish definitive efficacy.
Studietyp
Interventionell
Inskrivning (Beräknad)
100
Fas
- Fas 1
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Larry Powalisz
- Telefonnummer: 3217880850
- E-post: research@adiamed.com
Studieorter
-
-
Florida
-
Winter Park, Florida, Förenta staterna, 32789
- Rekrytering
- Adia Med Of Winter Park
-
Kontakt:
- Larry Powalisz
- Telefonnummer: 3217880850
- E-post: research@adiamed.com
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- Age 18-85 years
- Chronic lower back pain ≥3 months
- MRI within 12 months demonstrating one or more qualifying diagnoses:
Degenerative disc disease Disc bulge or herniation Modic changes Facet joint osteoarthritis Mixed disc and facet pathology
- Baseline VAS-Average ≥4/10
- Able to comply with study visits and procedures
- Able to provide written informed consent
- Able to meet study cost requirements ($5,000 study fee plus MRI costs, if applicable) as described in the informed consent
Exclusion Criteria:
- Pregnancy or breastfeeding
- Prisoners or decisionally impaired adults
- Active malignancy (except non-melanoma skin cancer)
- Immunodeficiency or active systemic infection
- Prior lumbar surgery within 12 months
- Epidural steroid or facet joint injection within 3 months
- Participation in another interventional trial within 30 days
- Known allergy to product components
- Any medical condition posing unacceptable risk per investigator judgment.
- Prior stem cell therapy: History of stem cell therapy (including umbilical cord blood-derived stem cells or exosomes) at any time prior to screening
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Stamcell
|
Intravenös infusion av kryokonserverad allogen navelsträngsblodsprodukt innehållande livskraftiga mononukleära celler (inklusive hematopoetiska och mesenkymala stam-/strömceller) och exosomer.
|
|
Placebo-jämförare: Placebo Control (with Crossover)
|
Matched placebo intravenous infusion (administered in the same volume and manner as stem cell and exosome product).
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Average Low Back Pain Intensity From Baseline to Month 3
Tidsram: Baseline to Month 3
|
Measured using the Visual Analog Scale (VAS-Average), a 0-10 scale assessing average low back pain intensity over the past week, with higher scores indicating greater pain severity.
|
Baseline to Month 3
|
|
Change in Functional Disability From Baseline to Month 3
Tidsram: Baseline to Month 3
|
Measured using the Oswestry Disability Index (ODI), a validated questionnaire assessing disability related to low back pain, scored from 0-100%, with higher scores indicating greater disability.
|
Baseline to Month 3
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Tidsram: Baseline through Month 6
|
Assessment of safety and tolerability based on the frequency, severity, and relationship of adverse events following investigational infusion, graded using Common Terminology Criteria for Adverse Events (CTCAE v5.0).
|
Baseline through Month 6
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Huvudutredare: Evan Thomas, MD, PhD, Adia Med of Winter Park LLC
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Beräknad)
16 juni 2026
Primärt slutförande (Beräknad)
1 januari 2028
Avslutad studie (Beräknad)
1 januari 2028
Studieregistreringsdatum
Först inskickad
8 maj 2026
Först inskickad som uppfyllde QC-kriterierna
8 maj 2026
Första postat (Faktisk)
14 maj 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
17 juni 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
16 juni 2026
Senast verifierad
1 juni 2026
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- Adia Med LBP Research Study
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Ja
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
produkt tillverkad i och exporterad från U.S.A.
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .